Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by StockNews.com

StockNews.com started coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a report released on Monday morning. The firm issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Trading Down 1.2 %

NYSE BTX opened at $0.34 on Monday. The stock has a market capitalization of $19.75 million, a price-to-earnings ratio of -0.15 and a beta of 4.61. The stock has a 50-day moving average of $0.35 and a 200 day moving average of $0.96. Brooklyn ImmunoTherapeutics has a twelve month low of $0.17 and a twelve month high of $10.10.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.